Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that ...

Novo Nordisk NVO announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) ...

This follows recent successful efforts by the Trump administration to cut the price of this compound for certain patients.

While both drugs share the same active ingredient, their positioning, pricing, and regulatory pathways diverge sharply, ...

An Indian court has allowed Dr. Reddy’s Laboratories Ltd. to manufacture and export generic versions of Novo Nordisk A/S’s ...

Novo Nordisk said on Friday the European Medicines Agency's committee had issued a positive opinion for a higher dose of its ...

The share price of Danish pharmaceutical giant Novo Nordisk ( NVO +1.31%) hit a four-year low Monday, falling below $44 a share in early trading, a level the stock hasn't seen since July 2021. What's ...

The drug is marketed globally by Novo Nordisk as Ozempic for Type 2 diabetes and for obesity, and has been at the centre of a ...

A proposed new federal law could provide some competitive guardrails for the company's most important product.

Novo Nordisk in 2020 launched pivotal trials of its GLP-1 drug semaglutide in Alzheimer's patients based on studies in humans ...